9IP1 Stock Overview Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Rocket Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Rocket Pharmaceuticals Historical stock prices Current Share Price US$12.18 52 Week High US$28.41 52 Week Low US$10.54 Beta 1 1 Month Change -0.082% 3 Month Change -16.52% 1 Year Change -53.19% 3 Year Change -32.71% 5 Year Change -44.64% Change since IPO 27.47%
Recent News & Updates Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million. Dec 12
Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million.
New minor risk - Profitability Nov 17
Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease Sep 17
Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board Sep 12
Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) Jun 28 See more updates Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million. Dec 12
Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million.
New minor risk - Profitability Nov 17
Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease Sep 17
Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board Sep 12
Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) Jun 28
Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct) May 11
New minor risk - Profitability May 08
Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024 May 01
Insider recently sold €284k worth of stock Apr 12
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia Apr 02 Rocket Pharmaceuticals, Inc. Announces Executive Appointments
No longer forecast to breakeven Feb 28
CEO & Director recently sold €561k worth of stock Feb 23
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) Feb 13
New minor risk - Profitability Jan 19
Forecast to breakeven in 2026 Dec 31
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director Dec 12
New major risk - Revenue and earnings growth Nov 08
New minor risk - Profitability Oct 11
Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) Oct 05
Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease Jun 01
CEO & Director recently sold €81k worth of stock May 21
Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) May 10
Insufficient new directors May 04
Insider recently sold €64k worth of stock Feb 23
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease Feb 08
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM Jan 10
Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting Dec 24
Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others, Dec 03
Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) Oct 13
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 Oct 01
Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million. Sep 22
Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million. Sep 21
Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President Jul 28
Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct) May 20
Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 18
Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022 May 02
Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors Apr 06 Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance Mar 10
CEO & Director recently bought €334k worth of stock Feb 09
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting Dec 14
Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24Th Annual Meeting of the American Society of Gene and Cell Therapy May 14
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I Mar 11
New 90-day high: €52.50 Feb 05 Rocket Pharmaceuticals, Inc. Announces Executive Appointments
Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $260.000048 million. Dec 11
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting Dec 10
New 90-day high: €50.00 Dec 10
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting Dec 09
New 90-day high: €28.40 Nov 19
Inotek Pharmaceuticals Corporation Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis Nov 14
Rocket Pharmaceuticals, Inc. Presents Positive LAD-L Clinical Update and Comprehensive IMO Preclinical Review At the European Society for Immunodeficiencies 2020 Meeting Oct 17
New 90-day high: €25.00 Oct 16
New 90-day high - €22.40 Aug 07
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Microcap Index Jul 02 Shareholder Returns 9IP1 DE Biotechs DE Market 7D 4.1% 2.5% -0.4% 1Y -53.2% -10.2% 7.9%
See full shareholder returns
Return vs Market: 9IP1 underperformed the German Market which returned 7.9% over the past year.
Price Volatility Is 9IP1's price volatile compared to industry and market? 9IP1 volatility 9IP1 Average Weekly Movement 11.7% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 9IP1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9IP1's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy.
Show more Rocket Pharmaceuticals, Inc. Fundamentals Summary How do Rocket Pharmaceuticals's earnings and revenue compare to its market cap? 9IP1 fundamental statistics Market cap €1.11b Earnings (TTM ) -€250.44m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 9IP1 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$258.08m Earnings -US$258.08m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 02:24 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Rocket Pharmaceuticals, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Zemansky BofA Global Research Gregory Harrison BofA Global Research Yun Zhong BTIG
Show 22 more analysts 
